Axitinib: Optimizando el tratamiento de segunda línea del cáncer renal - page 18

Axitinib es efectivo después de anti PD1/PDL1

‐

L Albiges et al 2015 R Nadal et al 2016

; .

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,8,9,10,11,12,13,14,15,16,17 19,20,21,22,23,24,25,26,27,28,...44